Teva UK Limited Welcomes DH Generic Substitution Consultation

CASTLEFORD, England, January 5 - Teva UK Limited has today welcomed the Department of Health's (DH)
preferred proposal on generic substitution, which follows the announcement of
a three-month consultation.

The proposal favoured by DH would allow dispensers to switch a
prescription from a named branded medicine to a cheaper generic equivalent
for a selected list of medicines, with an opt-out endorsement.

Says Richard Daniell, Commercial Operations Officer at Teva: "Teva
wholeheartedly supports DH's preferred proposal. Generic medicines maintain
the same standards of quality, safety and efficacy as the originator brands
at an average of 20% of the cost. The UK generics industry already saves the
NHS GBP8.6 billion each year(1), and this is the ideal opportunity to save
millions - or even billions - more whilst providing proven and effective
healthcare for millions of patients across the UK."

The vast majority of generic medicines are interchangeable with their
branded equivalents. Adds Richard: "The DH proposal takes into account the
small number of drugs which should not be changed once the patient is
initiated - from the brand to the generic or vice-versa. Teva's position is
that patient safety always comes first, and the proposals reflect that the
vast majority of drugs can be substituted and save the NHS even more each
year without compromising patient safety."

DH will now start the three-month consultation into the proposals.
Richard concludes, "The move to generic substitution represents true value
for money for the tax payer at a time when the NHS needs to be at its most
efficient."

To find out more about Teva, visit www.tevauk.com.

(1) BGMA Press Release 05/01/2010

Notes to editors:

Teva UK Limited is one of the UK's leading pharmaceutical manufacturers,
with a presence in the generics, branded respiratory and hospitals markets.
Measured by the volume of boxes supplied, it is the biggest single medicines
supplier to the NHS. With over 500 product lines, it has the widest range of
any UK generic pharmaceutical company and has a number of respiratory
products including the Qvar(R) (beclometasone dipropionate) CFC-free inhaler.

For media enquiries, telephone the Teva Communications team on +44-(0)1977-628500, or email media.enquiries at tevauk.com.